A Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of XTR006 in Healthy Chinese Volunteers
Latest Information Update: 09 May 2024
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Sinotau Pharmaceuticals
- 01 May 2024 Status changed from recruiting to completed.
- 07 Dec 2023 New trial record